

INFORMATION DISCLOSURE
CITATION

(Use several sheets if necessary)

APPLN. NO.

08/460,186

APPLICANT

VON BORSTEL et al.

FILING DATE

June 2, 1995

ATTY. DKT. NO.

1331-138

GROUP

1623

U.S. PATENT DOCUMENTS

*EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
INITIAL						
<i>m</i>	AR	5,246,708	09/1993	von Borstel et al.	—	—
	BR	5,470,838	11/1995	von Borstel et al.	—	—
	CR	5,583,117	12/1996	von Borstel et al.	—	—
	DR	5,691,320	11/1997	von Borstel et al.	—	—
	ER	5,736,531	04/1998	von Borstel et al.	—	—
	FR	5,770,582	06/1998	von Borstel et al.	—	—
	GR	5,968,914	10/1999	von Borstel et al.	—	—
	HR	6,020,320	02/2000	von Borstel et al.	—	—
	IR	6,020,322	02/2000	von Borstel et al.	—	—
	JR	6,054,441	04/2000	von Borstel et al.	—	—
	KR	6,060,459	05/2000	von Borstel et al.	—	—
	LR	6,103,701	08/2000	von Borstel et al.	—	—
	MR	6,232,298	05/2001	von Borstel et al.	—	—
	NR	6,255,290	07/2001	von Borstel et al.	—	—
	OR	6,258,795	07/2001	von Borstel et al.	—	—
	PR	6,274,563	08/2001	von Borstel et al.	—	—
	QR	6,297,222	10/2001	von Borstel et al.	—	—
	RR	6,306,834	10/2001	von Borstel et al.	—	—
	SR	6,316,426	11/2001	von Borstel et al.	—	—
	TR	6,329,350	12/2001	von Borstel et al.	—	—
	UR	6,344,447	02/2002	von Borstel et al.	—	—
	VR	6,348,451	02/2002	von Borstel et al.	—	—
	WR	6,403,565	06/2002	von Borstel et al.	—	—
	XR	6,417,170	07/2002	von Borstel et al.	—	—
	YR	6,465,440	10/2002	von Borstel et al.	—	—
	ZR	6,472,378	10/2002	von Borstel et al.	—	—
<i>m</i>	AAR	6,743,782	06/2004	von Borstel et al.	—	—

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
BBR					
CCR					


OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

<i>m</i>	DDR	Kelsen et al. "Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer" J. Clin. Oncol. 15:1511-1517 (1997)
<i>m</i>	EER	Peters et al. "In vitro biochemical and in vivo biologicals studies of the uridine 'rescue' of 5-fluorouracil" Brit. J. Cancer 57:259-265 (1988)
	FFR	
	GGR	

*Examiner *Alman* Date Considered *1/9/06*

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)


**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

APPLN. NO.

08/460,186

ATTY. DKT. NO.

1331-138

APPLICANT

VON BORSTEL et al.

FILING DATE

June 2, 1995

GROUP

1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
u	AR 5,246,708	09/1993	von Borstel et al.	—	—	
	BR 5,470,838	11/1995	von Borstel et al.	—	—	
	CR 5,583,117	12/1996	von Borstel et al.	—	—	
	DR 5,691,320	11/1997	von Borstel et al.	—	—	
	ER 5,736,531	04/1998	von Borstel et al.	—	—	
	FR 5,770,582	06/1998	von Borstel et al.	—	—	
	GR 5,968,914	10/1999	von Borstel et al.	—	—	
	HR 6,020,320	02/2000	von Borstel et al.	—	—	
	IR 6,020,322	02/2000	von Borstel et al.	—	—	
	JR 6,054,441	04/2000	von Borstel et al.	—	—	
	KR 6,060,459	05/2000	von Borstel et al.	—	—	
	LR 6,103,701	08/2000	von Borstel et al.	—	—	
	MR 6,232,298	05/2001	von Borstel et al.	—	—	
	NR 6,255,290	07/2001	von Borstel et al.	—	—	
	OR 6,258,795	07/2001	von Borstel et al.	—	—	
	PR 6,274,563	08/2001	von Borstel et al.	—	—	
	QR 6,297,222	10/2001	von Borstel et al.	—	—	
	RR 6,306,834	10/2001	von Borstel et al.	—	—	
	SR 6,316,426	11/2001	von Borstel et al.	—	—	
	TR 6,329,350	12/2001	von Borstel et al.	—	—	
	UR 6,344,447	02/2002	von Borstel et al.	—	—	
	VR 6,348,451	02/2002	von Borstel et al.	—	—	
	WR 6,403,565	06/2002	von Borstel et al.	—	—	
	XR 6,417,170	07/2002	von Borstel et al.	—	—	
	YR 6,465,440	10/2002	von Borstel et al.	—	—	
	ZR 6,472,378	10/2002	von Borstel et al.	—	—	
u	AAR 6,743,782	06/2004	von Borstel et al.	—	—	

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
BBR					
CCR					

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

u	DDR	Kelsen et al. "Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer" J. Clin. Oncol. 15:1511-1517 (1997)
u	EER	Peters et al. "In vitro biochemical and in vivo biologicals studies of the uridine 'rescue' of 5-fluorouracil" Brit. J. Cancer 57:259-265 (1988)
	FFR	
	GGR	

*Examiner

u

Date Considered

11/9/05

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)